What is Zacks Research’s Forecast for DYAI Q2 Earnings?

Dyadic International Inc. (NASDAQ:DYAI) – Zacks Research issued their Q2 2026 earnings estimates for shares of Dyadic International in a report released on Wednesday, May 20th. Zacks Research analyst J. Vandermosten expects that the biotechnology company will post earnings of ($0.03) per share for the quarter. The consensus estimate for Dyadic International’s current full-year earnings is ($0.12) per share. Zacks Research also issued estimates for Dyadic International’s Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.02) EPS and FY2028 earnings at ($0.01) EPS.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dyadic International in a research note on Friday, March 27th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $3.00.

Dyadic International Trading Up 2.3%

Shares of NASDAQ:DYAI opened at $0.74 on Thursday. Dyadic International has a 12-month low of $0.65 and a 12-month high of $1.35. The business has a 50 day moving average of $0.81 and a 200-day moving average of $0.87. The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 4.08. The stock has a market cap of $26.88 million, a PE ratio of -3.21 and a beta of 1.18.

Dyadic International (NASDAQ:DYAI) last released its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The company had revenue of $1.11 million during the quarter, compared to the consensus estimate of $0.90 million. Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%.

Hedge Funds Weigh In On Dyadic International

A number of hedge funds have recently bought and sold shares of DYAI. Geode Capital Management LLC raised its stake in Dyadic International by 13.7% in the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 36,266 shares in the last quarter. Marathon Capital Management grew its position in shares of Dyadic International by 142.9% during the 4th quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 50,000 shares in the last quarter. Apis Capital Advisors LLC bought a new position in shares of Dyadic International during the third quarter worth approximately $1,817,000. Landscape Capital Management L.L.C. bought a new position in shares of Dyadic International during the third quarter worth approximately $190,000. Finally, Truist Financial Corp raised its position in shares of Dyadic International by 30.5% in the third quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock valued at $385,000 after buying an additional 76,200 shares in the last quarter. 27.95% of the stock is owned by institutional investors.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.